A randomised, double-blind, vehicle-controlled study to evaluate the efficacy and safety of MAS063D (Atopiclair®), in the treatment of mild to moderate atopic dermatitis

G. Belloni, S. Pinelli, S. Veraldi

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

MAS063D (Atopiclair®) is a hydrolipidic cream that has been developed for the management of atopic dermatitis (AD). The putative active ingredients of MAS063D are hyaluronic acid, telmesteine, Vitis vinifera, glycyrrhetinic acid. A five-week study in 30 adult patients with mild to moderate AD showed that MAS063D offered significant benefits over a vehicle-only control. MAS063D improved the total body area affected (17.2% → 13.2%, p <0.001), itch score (2.7 → 1.3 on a 10-point scale, P = 0.001) and EASI score (28.3 → 24.3, p = 0.024) after 22 days treatment compared to baseline. The patients' opinion of MAS063D (patient's view of itch control, and view of study substance) was rated by participating patients as significantly better than control (p = 0.008, p = 0.042 respectively). Based on these preliminary results in a small scale study, it is suggested that MAS063D is a possible new treatment option for improving signs and symptoms in adults with mild to moderate AD.

Original languageEnglish
Pages (from-to)31-36
Number of pages6
JournalEuropean Journal of Dermatology
Volume15
Issue number1
Publication statusPublished - Jan 2005

Fingerprint

Atopic Dermatitis
Safety
Glycyrrhetinic Acid
Vitis
Hyaluronic Acid
Therapeutics
Signs and Symptoms
MAS063DP

Keywords

  • Atopic dermatitis
  • Eczema
  • Emollient
  • Itching
  • MAS063D

ASJC Scopus subject areas

  • Dermatology

Cite this

@article{4f997e956fe747c3b23fa220b037a283,
title = "A randomised, double-blind, vehicle-controlled study to evaluate the efficacy and safety of MAS063D (Atopiclair{\circledR}), in the treatment of mild to moderate atopic dermatitis",
abstract = "MAS063D (Atopiclair{\circledR}) is a hydrolipidic cream that has been developed for the management of atopic dermatitis (AD). The putative active ingredients of MAS063D are hyaluronic acid, telmesteine, Vitis vinifera, glycyrrhetinic acid. A five-week study in 30 adult patients with mild to moderate AD showed that MAS063D offered significant benefits over a vehicle-only control. MAS063D improved the total body area affected (17.2{\%} → 13.2{\%}, p <0.001), itch score (2.7 → 1.3 on a 10-point scale, P = 0.001) and EASI score (28.3 → 24.3, p = 0.024) after 22 days treatment compared to baseline. The patients' opinion of MAS063D (patient's view of itch control, and view of study substance) was rated by participating patients as significantly better than control (p = 0.008, p = 0.042 respectively). Based on these preliminary results in a small scale study, it is suggested that MAS063D is a possible new treatment option for improving signs and symptoms in adults with mild to moderate AD.",
keywords = "Atopic dermatitis, Eczema, Emollient, Itching, MAS063D",
author = "G. Belloni and S. Pinelli and S. Veraldi",
year = "2005",
month = "1",
language = "English",
volume = "15",
pages = "31--36",
journal = "European Journal of Dermatology",
issn = "1167-1122",
publisher = "NLM (Medline)",
number = "1",

}

TY - JOUR

T1 - A randomised, double-blind, vehicle-controlled study to evaluate the efficacy and safety of MAS063D (Atopiclair®), in the treatment of mild to moderate atopic dermatitis

AU - Belloni, G.

AU - Pinelli, S.

AU - Veraldi, S.

PY - 2005/1

Y1 - 2005/1

N2 - MAS063D (Atopiclair®) is a hydrolipidic cream that has been developed for the management of atopic dermatitis (AD). The putative active ingredients of MAS063D are hyaluronic acid, telmesteine, Vitis vinifera, glycyrrhetinic acid. A five-week study in 30 adult patients with mild to moderate AD showed that MAS063D offered significant benefits over a vehicle-only control. MAS063D improved the total body area affected (17.2% → 13.2%, p <0.001), itch score (2.7 → 1.3 on a 10-point scale, P = 0.001) and EASI score (28.3 → 24.3, p = 0.024) after 22 days treatment compared to baseline. The patients' opinion of MAS063D (patient's view of itch control, and view of study substance) was rated by participating patients as significantly better than control (p = 0.008, p = 0.042 respectively). Based on these preliminary results in a small scale study, it is suggested that MAS063D is a possible new treatment option for improving signs and symptoms in adults with mild to moderate AD.

AB - MAS063D (Atopiclair®) is a hydrolipidic cream that has been developed for the management of atopic dermatitis (AD). The putative active ingredients of MAS063D are hyaluronic acid, telmesteine, Vitis vinifera, glycyrrhetinic acid. A five-week study in 30 adult patients with mild to moderate AD showed that MAS063D offered significant benefits over a vehicle-only control. MAS063D improved the total body area affected (17.2% → 13.2%, p <0.001), itch score (2.7 → 1.3 on a 10-point scale, P = 0.001) and EASI score (28.3 → 24.3, p = 0.024) after 22 days treatment compared to baseline. The patients' opinion of MAS063D (patient's view of itch control, and view of study substance) was rated by participating patients as significantly better than control (p = 0.008, p = 0.042 respectively). Based on these preliminary results in a small scale study, it is suggested that MAS063D is a possible new treatment option for improving signs and symptoms in adults with mild to moderate AD.

KW - Atopic dermatitis

KW - Eczema

KW - Emollient

KW - Itching

KW - MAS063D

UR - http://www.scopus.com/inward/record.url?scp=13844292516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13844292516&partnerID=8YFLogxK

M3 - Article

C2 - 15701590

AN - SCOPUS:13844292516

VL - 15

SP - 31

EP - 36

JO - European Journal of Dermatology

JF - European Journal of Dermatology

SN - 1167-1122

IS - 1

ER -